Cargando…

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis

BACKGROUND: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) in patients newly diagnosed with rheumatoid arthritis (RA), both as monotherapy and in combination with other antirheumatic drugs. We aimed to study the relationship betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergstra, Sytske Anne, Allaart, Cornelia F., van den Berg, Rosaline, Chopra, Arvind, Govind, Nimmisha, Huizinga, Tom W. J., Landewe, Robert B. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700534/ https://www.ncbi.nlm.nih.gov/pubmed/29166919 http://dx.doi.org/10.1186/s13075-017-1468-9

Ejemplares similares

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis
por: Bergstra, Sytske Anne, et al.
Publicado: (2015)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

Osteoporosis in Black South Africans With Rheumatoid Arthritis
por: Naidoo, Tania, et al.
Publicado: (2023)

Comorbidities in Black South Africans with established rheumatoid arthritis
por: Lala, Vikash, et al.
Publicado: (2022)

Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
por: Isozaki, Takeo, et al.
Publicado: (2010)

Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis
por: Hayashi, Keigo, et al.
Publicado: (2020)

The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Pott's disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy
por: Zorlu, Mehmet, et al.
Publicado: (2013)

Three handy tips and a practical guide to improve your propensity score models
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis
por: Patanè, Marinella, et al.
Publicado: (2013)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
por: Fleischmann, R, et al.
Publicado: (2016)

Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
por: Emery, Paul, et al.
Publicado: (2023)

Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
por: Lee, Won-Seok, et al.
Publicado: (2016)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study
por: Morrison, Alan, et al.
Publicado: (2021)

Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis
por: Nozaki, Yuji, et al.
Publicado: (2021)

Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report
por: Jeiziner, Chiara, et al.
Publicado: (2022)

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’ – authors’ reply
por: Markusse, Iris M., et al.
Publicado: (2015)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Qiu, Qi, et al.
Publicado: (2017)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nbjnpa6u7fus6ej55hbnk7nnqh